<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="128413">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430455</url>
  </required_header>
  <id_info>
    <org_study_id>6333</org_study_id>
    <nct_id>NCT01430455</nct_id>
  </id_info>
  <brief_title>Tranylcypromine Treatment of Bipolar Depression</brief_title>
  <official_title>Tranylcypromine Treatment of Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to investigate whether tranylcypromine (Parnate®) might be an effective
      treatment of bipolar depression. New treatments are needed, as there is little evidence that
      standard antidepressants are effective in treating this condition, and the two antipsychotic
      medications that have indications for bipolar depression can cause substantial side effects.
      This study will focus specifically on currently depressed outpatients having a bipolar
      history for whom at least one standard antidepressant medication was ineffective. Patients
      will be treated openly with tranylcypromine for 8-10 months, depending on treatment
      response.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression (HAMD)</measure>
    <time_frame>Weekly or bi-weekly for 16 week study duration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Illness (QIDS)</measure>
    <time_frame>Weekly or bi-weekly for entire 16 week study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Check List - 90 items (SCL-90)</measure>
    <time_frame>Administered four times throughout 16 week study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression Scale (PGI)</measure>
    <time_frame>Weekly or bi-weekly throughout the 16 week study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Clinical Monitoring Form (M-CMF)</measure>
    <time_frame>Weekly or bi-weekly throughout the 16 week study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Adjustment Scale (SAS)</measure>
    <time_frame>Administered four times throughout the 16 week study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bipolar Disorder I or II</condition>
  <arm_group>
    <arm_group_label>Tranylcypromine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active, open-label tranylcypromine treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranylcypromine</intervention_name>
    <description>Tranylcypromine, between 10 mg/day and 120 mg/day throughout 16 week study</description>
    <arm_group_label>Tranylcypromine</arm_group_label>
    <other_name>Parnate®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. History of Bipolar I, II

          2. Currently depressed (major depressive episode or depression NOS)

          3. Physically healthy or physically stable (i.e.,No changes in medical interventions in
             past three months or likely for the next three months)

          4. On stable and effective mood stabilizer or hypomania deemed sufficiently mild to not
             require a mood stabilizer.

          5. Prior adequate trial on at least one antidepressant.

          6. Able to follow a tyramine-free diet

          7. Must speak English

        Exclusion Criteria:

          1. Current psychosis

          2. past psychosis not occurring during an episode of mania or depression

          3. prior nonremission to tranylcypromine 60 mg/d (or greater)

          4. currently taking effective medication precluded while taking a MAOI (e.g., a
             psychostimulant or a serotonin re-uptake inhibitor)

          5. current (last six months) drug or alcohol abuse or dependence

          6. significant suicide risk

          7. significant cardiovascular risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vito Agosti, M.S.W.</last_name>
    <phone>212-543-5605</phone>
    <email>agostiv@nyspi.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan W Stewart, M.D.</last_name>
    <phone>212-543-5745</phone>
    <email>jws6@columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vito Agosti, M.S.W.</last_name>
      <phone>212-543-5605</phone>
      <email>agostiv@nyspi.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan W Stewart, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David J Hellerstein, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deborah A Deliyannides, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick J McGrath, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robin Bell, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depression-nyc.org/</url>
    <description>Depression Evaluation Service</description>
  </link>
  <verification_date>September 2011</verification_date>
  <lastchanged_date>December 14, 2011</lastchanged_date>
  <firstreceived_date>September 6, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Episode</keyword>
  <keyword>Depression NOS</keyword>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Bipolar Disorder I</keyword>
  <keyword>Bipolar Disorder II</keyword>
  <keyword>Bipolar Depression</keyword>
  <keyword>Major Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tranylcypromine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
